A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting

  • Jack C
  • Lalloo U
  • Karim Q
 et al. 
  • 32

    Readers

    Mendeley users who have this article in their library.
  • 57

    Citations

    Citations of this article.

Abstract

To determine the feasibility and effectiveness of integrating highly active antiretroviral therapy (HAART) into existing tuberculosis directly observed therapy (TB/DOT) programs, we performed a pilot study in an urban TB clinic in South Africa. Patients with smear-positive pulmonary TB were offered HIV counseling and testing. Twenty HIV-positive patients received once-daily didanosine (400 mg) plus lamivudine (300 mg) plus efavirenz (600 mg) administered concomitantly with standard TB therapy Monday to Friday and self-administered on weekends. After completing TB therapy, patients were referred to an HIV clinic for continued treatment. At baseline, patients had a mean CD4 count of 230 cells/mm(3) (range: 24-499 cells/mm(3)) and a mean viral load of 5.75 log(10) (range: 3.81-7.53 log(10)). Seventeen completed combined standard TB and HIV therapy; 16 of 20 (80%) patients enrolled and 15 of 17 (88%) patients completing standard TB therapy achieved a viral load

Author-supplied keywords

  • Access to antiretroviral therapy
  • HAART
  • HIV/AIDS
  • Once-daily HAART
  • Tuberculosis directly observed therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Christopher Jack

  • Umesh Lalloo

  • Quarraisha Abdool Karim

  • Salim Abdool Karim

  • Wafaa El-Sadr

  • Sharon Cassol

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free